Full Title 1719-001: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion Study Treatment Oral PRMT5 inhibitor MRTX1719 Eligibility/Info Phase 1 - advanced MTAP deleted solid tumor that has continued to grow despite treatment with standard anti-cancer therapies. Contact For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075. Locations Babylon Medical Oncology Central Park Medical Oncology Eastchester Cancer Center Lake Success Medical Oncology Patchogue Medical Oncology Port Jefferson Medical Oncology Port Jefferson Station Medical Oncology Riverhead Medical Oncology
Contact us today to request an appointment.Virtual & Telemedicine available.
